Shots:
- The P-III ENSEMBLE trial to evaluate the efficacy and safety of Janssen’s COVID-19 vaccine candidate in protecting mod-to-severe COVID-19 in 43,783 participants accruing 468 symptomatic cases with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints
- Results: The level of protection against mod-to-severe COVID-19 infection was 72% in the US, 66% in Latin America, 57% in South Africa; 28 days post-vaccination and 85% effective in preventing severe disease and complete protection & death as of day 28
- The company plans to provide affordable COVID-19 vaccine at a not-for-profit basis for emergency pandemic use, pending regulatory authorizations
Click here to read full press release/ article | Ref: J&J | Image: M3 India
The post Johnson & Johnson Report Results from P-III ENSEMBLE Trial for COVID-19 Vaccine first appeared on PharmaShots.
